Form 4: Palatin Technologies Director Receives Stock Options and Restricted Share Units

Director Robert K. deVeer Jr. acquired 12,000 restricted share units and 17,000 stock options in Palatin Technologies, according to a recent SEC filing.

Summary

• On July 15, 2024, Robert K. deVeer Jr., a director of Palatin Technologies Inc., acquired 12,000 restricted share units and 17,000 stock options.
• The restricted share units were granted under the 2011 Stock Incentive Plan and each represents the right to receive one share of common stock, vesting on June 4, 2025.
• The stock options have an exercise price of $1.83 and also vest on June 4, 2025, with a prorated vesting schedule if the director doesn't serve until June 30, 2025.
• Following these transactions, deVeer directly owns 38,065 shares of common stock and 57,780 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of stock options and restricted share units aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. Similar grants are often seen at companies like Amgen, Gilead Sciences, and Biogen.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options and restricted stock units to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to incentivize long-term performance and alignment with shareholder interests.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates